Moderna

---

Moderna offers three different COVID-19 vaccines tailored to different age groups of patients. Moderna’s available COVID-19 vaccines are:

• Moderna’s COVID-19 vaccine pediatric dose (patient 6 months to 11 years old)
• Spikevax (patients 12 years and older)
• mNexSpike (patients 65 years and older, as well as patients 12 years and older with a high-risk condition)

PCA members must sign a participation agreement and declaration form. Please contact Amy at abullock@primarycarealliance.com to confirm you are registered for the Moderna program.

Pfizer

---

Pfizer offers three different COVID-19 vaccines tailored to different age groups of patients. Pfizer’s available COVID-19 vaccines are:

• BioNTech Pfizer mRNA pediatric dose (patients 6 months to 4 years old)
  • Must be reconstituted
• BioNTech Pfizer mRNA pediatric dose (patients 5 to 11 years old)
• Comirnaty (patients 12 years and older)

Pfizer is offering a 2% discount on reservations placed by July 31, 2025.

PCA members must specifically sign up for discounts on COVID-19 vaccines through the Pfizer portal. Please contact Amy at abullock@primarycarealliance.com to confirm you are registered for these discounts.

Sanofi

---

While reservations are not available for Sanofi yet, this year Sanofi will offer Novavax’s COVID-19 vaccine, Nuvaxovid, and will be for sale starting sometime in September or October on a first come first serve basis.

• Nuvaxovid (patients 12 years and older)
  • Adjuvanted vaccine, not mRNA

Those wishing to purchase Nuvaxovid when it is on sale this fall can purchase on Sanofi’s website www.VaccineShop.com.

Conclusion

---

As always, we recommend that each clinic review its COVID-19 vaccine usage for this year before reserving doses for the upcoming season. If you have any questions, please don’t hesitate to contact us by emailing Amy at abullock@primarycarealliance.com.

Merck’s Enflonsia Recommended:

---

Merck’s new RSV shot Enflonsia is now recommended by the ACIP. The committee approved one dose to be given for infants younger than 8 months of age who are born during or entering their first RSV season and who are not already protected by a maternal RSV vaccine (Pfizer’s Abrysvo). 

What is Enflonsia?

Enflonsia is a monoclonal antibody for RSV, like Sanofi’s Beyfortus, it is a form of passive immunization for RSV, not a vaccine. Unlike Sanofi’s Beyfortus, which can be given to high-risk infants during their second RSV season, Enflonsia is currently only approved to be given to infants during their first RSV season. However, Enflonsia is the first and only RSV preventative option for infants that uses the same dose (0.7mL) regardless of the patient’s weight.

The new ACIP recommendations will be published in the Morbidity and Mortality Weekly Report (MMWR) sometime in the next few months. Once the recommendations are published in the MMWR, insurance payers will determine when to add coverage for Enflonsia.

To read more on Enflonsia’s ACIP recommendation, click here to view Merck’s press release.

Pfizer’s Abrysvo Recommendation Update:

---

The ACIP’s recommendation of Pfizer’s Abrysvo has been expanded to now include adults ages 50 to 59 who are at increased risk for severe RSV disease. The prior recommendation was for high-risk adults ages 60 to 74, as well as all adults 75 years and older.

The CDC is still working on updating its webpage to include this new recommendation and help define the conditions that move patients into the high-risk category. Abrysvo is a Medicare Part D vaccine, so patients with Medicare should be sent to the pharmacy to receive this vaccine. However, the office should stock and offer Abrysvo to patients under age 65 who fall into the high-risk category. Currently, the ACIP recommends a single dose of RSV vaccine.

ACIP Reaffirms Recommendation on Yearly Flu Vaccinations:

---

The ACIP reaffirmed the recommendation that everyone ages 6 months and older be vaccinated against the flu each year, unless contraindicated for a specific patient.

The ACIP also voted that patients should only receive the seasonal flu vaccine in single-dose formulations that were free of thimerosal. Thimerosal is currently found in small amounts in multi-dose vials of Sanofi’s Fluzone, as well as Seqirus’ Afluria and Flucelvax. It is not found in single-dose vials or pre-filled syringes of these flu vaccines.

For customers who have prebooked multi-dose vials of Fluzone and would like to change their order, please call Sanofi’s customer service line at 1-800-VACCINE (822-2463).

PCA Members who have questions about their Seqirus reservation can contact Amy Bullock at abullock@primarycarealliance.com.